tbuckley/cabot-search huggingface dataset:
SAT0310 The Relationships between The Occurrence of Antibodies Used in Clinical Practice for Diagnosis of Lupus and Clinical Criteria Used in The Slicc Classification System
Authors: M. Dryglewska, M. Majdan, D. Suszek, A. Majdan, Z. Kiełbik, M. Grzywnowicz
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The relationships between the occurrence of antibodies used in clinical practice for diagnosis and monitoring of the disease activity of systemic lupus erythematosus (SLE) and clinical criteria used in the SLICC classification system are a matter of discussion. <h3>Objectives</h3> The aim of the study was to investigate whether there are any relationships between the presence of clinical criteria used in the SLICC classification system and the presence of antibodies characteristic for SLE detected by multiparametric assay. <h3>Methods</h3> The study involved 81 (72-female and 9-male) consecutive SLE patients treated in the Department of Rheumatology and Connective Tissue Diseases. All patients fulfilled the SLICC classification criteria of SLE and 21 SLE pts - criteria of secondary Antiphospholipid Syndrome (SAPS). The mean age in the study group was: 37.6±11.1 years (from 19 to 71), the duration of the disease was 9.6±8.5 (from 0 to 33) years and mean SLE activity (SLEDAI scale) 4.1±4.9 (from 0 to 22). The presence of antibodies (Ab) was determined by multiparametric enzyme-linked immunosorbent assay Polycheck Rheuma (Biocheck, GmbH, Münster, Germany). Statistical data analysis was performed using Statistica v10.0. <h3>Results</h3> In the studied group the following symptoms of SLE were found: malar rash – 46 pts, discoid rash -3 pts, photosensitivity – 34 pts, vasculitis – 21pts, oral ulcers – 22 pts, alopecia – 36 pts, musculoskeletal – 58 pts, arthritis – 36 pts, serositis – 14 pts, renal disorder – 7 pts, lupus nephritis – 33 pts, neurological disorders – 20 pts, hematologic disorders – 56 pts. In the examined group of 81 patients the following antibodies were detected: anti-dsDNA – 10 pts (12.3%), anti-Sm-9 pts (11.1%), anti-Rib P – 4 pts (4.9%), anti-Histons – 15 pts (18.5%), anti-Ro/SS-A 52 – 2pts (2.5%), anti-Ro/SS-A 60 – 22 pts (27.2%), anti-La/SS-B – 7 pts (8.6%), anti-Scl-70 – 3 pts (3.7%), anti-CENP-B – 1 pts (6.2%), anti-PM/Scl-100 – 3 pts (3.7%), anty-U1-snRNP – 9pts (11.1%), anti Ku – 5 pts (6.2%), anty-Jo-1 and anty-Mi-2 – 0 pts. In the data group of SLE patients, a statistically significant correlation was found only between vasculitis and presence of antibodies: anti-dsDNA (p=0.021, Φ Yule9a=0.27), anti-Ro SS-A 60 (p=0.027, Φ Yule9a=0.26), anti-Sm (p=0.028, Φ Yule9a=0.26). <h3>Conclusions</h3> In the SLE pts no significant association was found between the presence of clinical criteria used in the SLICC classification system and the antibodies used in clinical practice for diagnosis and monitoring of disease activity. Only vasculitis is significantly associated with the presence of anti-dsDNA, anti-Ro SS-A 60, and anti-Sm antibodies. <h3>Disclosure of Interest</h3> None declared
Concomitant Detection of BCR-ABL Translocation and JAK2 V617F Mutation In 6 Myeloproliferative Neoplasm at Diagnosis
Authors: M. Rosario Uriarte Escuder, Monica Cappetta, Gonzalo Manrique, Veronica Perez, María Noel Zubillaga, Victoria Elizondo, Susana Boschi, Ines Prosper, Rossana Bonomi, Santiago Pomoli, Lilian Diaz, Lem Martinez
Journal: Blood (2010)
Overall survival in newly diagnosed MM patients with del(17p): A report from the Connect MM Registry.
Authors: Jatin J. Shah, Rafat Abonour, Brian G. Durie, Jayesh Mehta, Mohit Narang, Howard R. Terebelo, Cristina Gasparetto, Kathleen Toomey, James W. Hardin, Shankar Srinivasan, Gail Larkins, Rosanna J. Ricafort, Yasir M. Nagarwala, Robert M. Rifkin
Journal: Journal of Clinical Oncology (2015)

8582 Background: Del(17p) is detected in 10%-15% of patients (pts) with MM and is associated with early relapse and short survival. There are limited data, no uniform or optimal treatment (Tx) approach, and questions on role of autologous stem cell transplant (ASCT). Connect MM, a prospective, observational, US, multicenter disease registry, contains the largest cohort of pts with newly diagnosed MM (NDMM) and del(17p). Disease characteristics and OS were analyzed in this cohort. Methods: Connect MM was initiated in Sep 2009. Data from pts (diagnosed ≤ 2 mo before study entry) enrolled up to Dec 2011 (N = 1493) at 234 sites were collected at baseline and quarterly thereafter. Outcomes data through Jun 30, 2014 for 1450 treated pts were analyzed. Survival analysis was adjusted for sex, race, therapy received, and ASCT. OS was estimated using Kaplan-Meier methods and comparisons were assessed using the log-rank test. Results: Del(17p) was detected (mainly by FISH) in 108 of the 1450 pts (7.4%). Median age was 69 y (range 27-89), 58% were male, 82% were Caucasian, and 33.3% had ISS stage III MM. Median follow-up was 33.5 mo (0.03-55.9 mo). Pts with del(17p) had lower median survival (38.6 mo vs not reached [NR], P < 0.001). Of pts initially treated with transplant intent, 44% (19/43) with del(17p) and 45% (274/615) without del(17p) received ASCT during first-line therapy. ASCT vs no ASCT was associated with a higher median OS in pts with del(17p) (NR vs 31.3 mo, P = 0.0177). By multivariate analysis of various baseline characteristics and therapy modalities, front-line ASCT was associated with a lower risk of death (HR 0.14, P = 0.008); hypercalcemia was associated with a higher risk of death (HR 3.06, P< 0.01) in pts with del(17p). Conclusions: Among pts with NDMM across a range of clinical practices, del(17p) was associated with inferior OS. Hypercalcemia may be a negative prognostic factor. Pts with del(17p) seem to benefit from ASCT. Analyses of the impact of novel combination therapies are being done and will be reported, as there is clear need to improve outcomes in this pt segment.
Arsenic Sulfide Binds c-CBL to Promote BCR-ABL Ubiquitination and Degradation In Chronic Myelogenous Leukemia.
Authors: Jian-Hua Mao, Xiao-Yan Sun, Jian-Xiang Liu, Qun-Ye Zhang, Ping Liu, Qiu-Hua Huang, Ke-Qin Li, Xiao-Wei Zhang, Quan Chen, Zhu Chen, Sai-Juan Chen
Journal: Blood (2010)
A Decade Of Imatinib As First-Line Treatment Of Chronic Myeloid Leukemia: A Single - Latin American Institution Experience
Authors: Alvaro Cabrera Garcia, Carolina Balderas Delgado, Juan Julio Kassack Ipiña, Christian Omar Ramos Peñafiel, Juan Collazo Jaloma, Adolfo Martínez Tovar, Hermelinda Gallardo, Humberto Baldemar Castellanos Sinco
Journal: Blood (2013)
Ebola Vaccination Using a DNA Vaccine Coated on PLGA‐PLL/γPGA Nanoparticles Administered Using a Microneedle Patch
Authors: Hung‐Wei Yang, Ling Ye, Xin Dong Guo, Chinglai Yang, Richard W. Compans, Mark R. Prausnitz
Journal: Advanced Healthcare Materials (2016)

Ebola DNA vaccine is incorporated into PLGA-PLL/γPGA nanoparticles and administered to skin using a microneedle (MN) patch. The nanoparticle delivery system increases vaccine thermostability and immunogenicity compared to free vaccine. Vaccination by MN patch produces stronger immune responses than intramuscular administration.
LOW Tranplant Related Mortality and LOW GRAFT Rejection After Related Haploidentical STEM CELL Transplantation (HAPLO-SCT) Prepared with NON Myeloablative CONDITIONING REGIMEN (NMA) and Posttransplant Cyclophosphamide for Advanced Lymphoid Malignancies.
Authors: Sabine Furst, Roberto Crocchiolo, Jean El-Cheikh, Catherine Faucher, Claire Oudin, Angela Granata, Geoffroy Venton, Claude Lemarie, Diane Coso, Reda Bouabdallah, Anne Marie Stoppa, Norbert Vey, Christian Chabannon, Didier Blaise
Journal: Blood (2012)
Outcome of Patients with AL Amyloidosis Who Do Not Achieve Hematologic Complete Response After Treatment with High Dose Melphalan and Autologous Transplantation: Results In a Series of 421 Patients
Authors: M. Teresa Cibeira, Vaishali Sanchorawala, David C Seldin, Karen Quillen, Nancy Andrea, J. Mark Sloan, Kathleen T Finn, John L Berk, Gheorghe Doros, Joan Blade, Martha Skinner
Journal: Blood (2010)
Identification of Recurring Tumor-Specific Somatic Mutations In Acute Myeloid Leukemia by Transcriptome Sequencing.
Authors: Philipp A Greif, Sebastian H Eck, Nikola Konstandin, Anna Benet-Pages, Annika Dufour, Anna Vetter, Henning Popp, Bettina Lorenz-Depiereux, Thomas Meitinger, Stefan K Bohlander, Tim M Strom
Journal: Blood (2010)
Investigational Agent MLN9708, An Oral Proteasome Inhibitor, in Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (MM): Results From the Expansion Cohorts of a Phase 1 Dose-Escalation Study
Authors: Paul G. Richardson, Rachid Baz, Luhua Wang, Andrzej J Jakubowiak, Deborah Berg, Guohui Liu, Neeraj Gupta, Alessandra Di Bacco, Ai-Min Hui, Sagar Lonial
Journal: Blood (2011)
Acquired in Vitro Resistance to Ibrutinib Is Associated with Transcriptional Re-Programming and Sustained Survival Signaling in Waldenströms Macroglobulinemia and Mantle Cell Lymphoma, Independent of BTK Cys481 Mutation
Authors: Kasyapa S. Chitta, Aneel Paulus, Maja Kuranz-Blake, Sharoon Akhtar, Anne J. Novak, Stephen M. Ansell, Morie A Gertz, Robert A Kyle, Peter Martin, Morton Coleman, Sikander Ailawadhi, Asher Chanan-Khan
Journal: Blood (2014)
GlioVis data portal for visualization and analysis of brain tumor expression datasets
Authors: Robert L. Bowman, Qianghu Wang, Angel Carro, Roel G.W. Verhaak, Massimo Squatrito
Journal: Neuro-Oncology (2016)

the effects they observed could be influenced by inhibition of other types of Trk receptors or signaling molecules downstream of Trk.We have recently started a series of experiments aiming to verify whether specific TrkB inhibition reduces glioma cell proliferation using ANA-12, a small-molecule selective TrkB antagonist.Our first results showed that ANA-12 effectively and dose-dependently reduces the viability of a human glioblastoma cell line with almost complete disappearance of cultured cells 72 hours after treatment (Fig. 1).Therefore, selective TrkB inhibition might prove to be an effective experimental therapeutic strategy, possibly with fewer off-target toxicities compared with multitarget drugs in patients with astrocytomas harboring oncogenic TrkB.
A Phase II Study Of V-BEAM (Bortezomib, Carmustine, Etoposide, Cytarabine, and Melphalan) As Conditioning Regimen Prior To Second Autologous Stem Cell Transplantation For Multiple Myeloma
Authors: Tzu-Fei Wang, Mark A. Fiala, Ningying Wu, Theresa Fletcher, Camille N. Abboud, Amanda F. Cashen, John F. Dipersio, Geoffrey L. Uy, Peter Westervelt, Keith E. Stockerl-Goldstein, Ravi Vij
Journal: Blood (2013)
Association of Bystander Cardiopulmonary Resuscitation With Overall and Neurologically Favorable Survival After Pediatric Out-of-Hospital Cardiac Arrest in the United States
Authors: Maryam Y. Naim, Rita V. Burke, Bryan F. McNally, Lihai Song, Heather M. Griffis, Robert A. Berg, Kimberly Vellano, David Markenson, Richard N. Bradley, Joseph W. Rossano
Journal: JAMA Pediatrics (2016)

There are few data on the prevalence or outcome of bystander cardiopulmonary resuscitation (BCPR) in children 18 years and younger.To characterize BCPR in pediatric out-of-hospital cardiac arrests (OHCAs).This analysis of the Cardiac Arrest Registry to Enhance Survival database investigated nontraumatic OHCAs in children 18 years and younger from January 2013 through December 2015.Bystander CPR, which included conventional CPR and compression-only CPR.Overall survival and neurologically favorable survival, defined as a Cerebral Performance Category score of 1 or 2, at the time of hospital discharge.Of the 3900 children younger than 18 years with OHCA, 2317 (59.4%) were infants, 2346 (60.2%) were female, and 3595 (92.2%) had nonshockable rhythms. Bystander CPR was performed on 1814 children (46.5%) and was more common for white children (687 of 1221 [56.3%]) compared with African American children (447 of 1134 [39.4%]) and Hispanic children (197 of 455 [43.3%]) (P < .001). Overall survival and neurologically favorable survival were 11.3% (440 of 3900) and 9.1% (354 of 3900), respectively. On multivariable analysis, BCPR was independently associated with improved overall survival (adjusted proportion, 13.2%; 95% CI, 11.81-14.58; adjusted odds ratio, 1.57; 95% CI, 1.25-1.96) and neurologically favorable survival (adjusted proportion, 10.3%; 95% CI, 9.10-11.54; adjusted odds ratio, 1.50; 95% CI, 1.21-1.98) compared with no BCPR (overall survival: adjusted proportion, 9.5%; 95% CI, 8.28-10.69; neurologically favorable survival: adjusted proportion, 7.59%; 95% CI, 6.50-8.68). For those with data on type of BCPR, 697 of 1411 (49.4%) received conventional CPR and 714 of 1411 (50.6%) received compression-only CPR. On multivariable analysis, only conventional CPR (adjusted proportion, 12.89%; 95% CI, 10.69-15.09; adjusted odds ratio, 2.06; 95% CI, 1.51-2.79) was associated with improved neurologically favorable survival compared with no BCPR (adjusted proportion, 9.59%; 95% CI, 6.45-8.61). There was a significant interaction of BCPR with age. Among infants, conventional BCPR was associated with improved overall survival and neurologically favorable survival while compression-only CPR had similar outcomes to no BCPR.Bystander CPR is associated with improved outcomes in pediatric OHCAs. Improving the provision of BCPR in minority communities and increasing the use of conventional BCPR may improve outcomes for children with OHCA.
Towards Regenerative Therapy for Thymic Insufficiency after Hematopoietic Stem Cell Transplantation: Generation of MTS24 Positive Definitive Endoderm from Murine Embryonic Stem Cells.
Authors: Erik Vroegindeweij, Wilhelmus J. Rombouts, Joanna A. Ropela, Shin-Ichi Nishikawa, Tom Cupedo, Jan J. Cornelissen
Journal: Blood (2007)
A PML–PPAR-δ Pathway for Fatty Acid Oxidation Regulates Hematopoietic Stem Cell Maintenance Through the Control of Asymmetric Division.
Authors: Keisuke Ito, Arkaitz Carracedo, Fumio Arai, Ugo Ala, David Avigan, Zachary Schafer, Ron M. Evans, Toshio Suda, Chih-Hao Lee, Pier Paolo Pandolfi
Journal: Blood (2012)
Molecular Characterization of the t(15;17)(q22;21) in Epirubicin-Related Acute Promyelocytic Leukaemia
Authors: Ashley Nicole Mays, Neil Osheroff, Carolyn Felix, Jo Ann Byl, Kandeepan Saravanamuttu, Andrew Peniket, Robert Corser, Cherry Chang, Christine Hoyle, Anne N Parker, Syed K Hasan, Francesco Lo-Coco, Ellen Solomon, David Grimwade
Journal: Blood (2008)
Connexin-43 Expression Regulates the Migration of Hematopoietic Stem Cells and Progenitors towards and From Bone Marrow.
Authors: Daniel Gonzalez-Nieto, Kyung-Hee Chang, Anja Koehler, Jorden Arnett, Susan Dunn, Lina Li, Gabriel Ghiaur, Amitava Sengupta, Glenn Fishman, David Gutstein, Roberto Civitelli, Luis Barrio, Matthias Gunzer, Jose Cancelas
Journal: Blood (2009)
Moderate alcohol intake is linked to lower risk of ischaemic stroke, study finds
Authors: Susan Mayor
Journal: BMJ (2016)

Light to moderate alcohol consumption of one to two drinks a day is associated with a lower risk of ischaemic stroke but does not affect haemorrhagic stroke risk, says a systematic review and meta-analysis which also confirms that heavy drinking increases the risk of all types of stroke.1

Observational studies have consistently reported lower risk of ischaemic heart disease with moderate alcohol intake, but the …
Ig/TCR Monitoring of High Level MRD within the GRAALL-2003 Adult ALL Trial Has More Impact in B Than T Lineage Cases.
Authors: Kheira Beldjord, Jean-Michel Cayuela, Helene Cavé, Nathalie Grardel, Françoise Huguet, Thibaut Leguay, Veronique Lheritier, Norbert Ifrah, Herve Dombret, Marie-Christine Béné, Elizabeth MacIntyre
Journal: Blood (2006)
Detection of Three Different MPLW515 Mutations in 10.1% of All JAK2 V617 Unmutated ET and 9.3% of All JAK2 V617F Unmutated OMF: A Study of 387 Patients.
Authors: Susanne Schnittger, Claudia Haferlach, Dietrich W. Beelen, Peter Bojko, Robert Dengler, Andrea Diestelrath, M.J. Eckart, Robert Eckert, Stefan Fries, Georg Köchling, Hans P. Laubenstein, Manfred Planker, Rudolf Pihusch, Wolfgang Kern, Torsten Haferlach
Journal: Blood (2007)
Reduced Risk of Residual Molecular and Hematological Relapse in Patients with Cml after KIRir-Ligand Mismatched Hematpoietic Stem Cell Transplantation.
Authors: Ahmet H. Elmaagacli, Hellmut Ottinger, Koldehoff Michael, Peceny Rudolf, Nina K. Steckel, Rudolf Trenschel, Harald Biersack, Hans Grosse-Wilde, Michael Flasshove, Dietrich W. Beelen
Journal: Blood (2004)
FRI0466 Increased Risk of Cancer in Patients with Psoriasis: A Nationwide Population Study
Authors: M.-J. Chiou, Y.-F. Fang, C.-F. Kuo
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Psoriasis is a chronic inflammatory disease that involves hyperproliferation of keratinocytes in the epidermis. Several studies have reported the relationship between psoriasis and cancer. Population-based estimates for cancer risks in patients with psoriasis is rare <h3>Objectives</h3> This study estimated the standardised incidence ratio (SIR) of cancer in patients with psoriasis in Taiwan. <h3>Methods</h3> The primary data source was the National Health Insurance database of Taiwan. We identified patients with psoriasis based on a rheumatologist or dermatologist diagnosis. Incident cases who were free or cancers in 2000 were identified. Incidence of cancer was estimated in both incident psoriasis patients and the general population in 2000. To measure the relative risk of cancer in psoriasis patients, we calculated a SIR for all types of cancers and also each cancer type. SIRs were computed as ratios of observed numbers of cancers to the expected number of cancers on the basis of age-specific incidence rates in 5-year age intervals of the entire NHI covered population in 2000. <h3>Results</h3> A total of 6,835 incident psoriasis patients (4,472 men, 2,363 women) were identified from 21,226,181 cancer-free beneficiaries of NHI in 2000. Mean age was 46.96 years in men and 41.27 years in women. After a median follow-up of 11 years, cancer was diagnosed in 527 patients with psoriasis and 860,084 in the general population. The most common cancers sites were gastrointestinal tract, oral cavity and pharynx in patients with psoriasis. The overall incidence of cancer was higher in psoriasis patients than the general population (6.92 vs. 3.34 cases per 1,000 patient-years, P&lt;0.001). Psoriasis was associated with an SIR of 1.15 (95% confidence interval [CI], 1.06–1.25) for cancer of all sites. The SIR was 1.95 (95% CI, 1.21–3.14) for skin cancers, 1.59 (95% CI, 1.26–2.02) for oral cavity and pharynx cancers and 1.14 (95% CI=1.00–1.30) for gastrointestinal tract cancers, respectively. <h3>Conclusions</h3> Compared with the general population, psoriasis patients have an increased risk for cancer. <h3>Disclosure of Interest</h3> None declared
SP0128 A Case of Difficult To Manage Rheumatoid Arthritis
Authors: L. Schoneveld
Journal: Annals of the Rheumatic Diseases (2016)

Rheumatoid arthritis (RA) is a chronic inflammatory disease that requires early treatment to prevent articular damage. Treatment with first line conventional DMARDs may be accompanied by side effects. Approximately 20 percent of patients with RA fail to respond to conventional DMARDs within 5 years and require biological DMARDs. However, a significant portion of the patients on tumor necrosis factor inhibitors, lose response over time or are unable to tolerate treatment. Furthermore, treatment with biological DMARDs may result in serious infectious complications. We will discuss a case of a 76 year old man with seropositive RA whose arthritis treatment was hampered by multiple problems during the course of his disease. <h3>Disclosure of Interest</h3> None declared
AB0608 Characteristic Adverse Events and Development of Digital Ulcers in Bosentan-Treated Japanese Patients with Digital Ulcers Secondary To Systemic Sclerosis
Authors: K. Takehara
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Only a few medications have been approved for the prevention and treatment of digital ulcers in Japan. Ethnicity has been reported to affect the severity and occurrence rate of digital ulcers, which are potentially caused by more common autoantibody prevalence in the systemic sclerosis (SSc) patients of some ethnic groups; however, information on Japanese and Asian patients is limited. In the present study, the adverse events and development of digital ulcers were investigated when bosentan was administered to Japanese SSc patients. We focused on liver function test abnormalities, which are one of the characteristic adverse events of bosentan, baseline patient characteristics, and the onset/resolution time of the associated adverse events. The occurrence and healing of digital ulcers over time in each patient were also examined. <h3>Methods</h3> Twenty-eight (28) patients were enrolled in 9 study sites in Japan. This was a multi-center, single arm, open-labeled study conducted in order to investigate the safety and efficacy of bosentan in Japanese patients who had or had a previous history of SSc-related digital ulcers. The safety of the drug was monitored and the clinical course of digital ulcers was assessed up to Week 52 of the treatment. <h3>Results</h3> The adverse events observed in ≥5% of patients, i.e., at least two patients during the 52-week treatment period, were upper respiratory tract infections (14/28, 50.0%), liver function test abnormalities (12/28, 42.9%), the development of new digital ulcers (7/28, 25.0%), anemia (5/28, 17.9%), peripheral edema (4/28, 14.3%), diarrhea (3/28, 10.7%), urinary tract infections (2/28, 7.1%), arthralgia (2/28, 7.1%), constipation (2/28, 7.1%), and herpes zoster (2/28, 7.1%). Of the 12 patients (42.9%) with liver function test abnormalities, 4 (14.3%) showed AST and/or ALT elevations &gt;3 × the upper limit of normal, occurring before Week 16 for two patients and after Week 16 for the other two. All elevated liver enzymes normalized upon withdrawal of the drug. During the 52-week observation period, 25% (7/28) of patients developed new digital ulcers, the mean (± SD) number of which was 0.6±1.3. <h3>Conclusions</h3> The adverse events observed in the present study were similar to those previously reported with the use of bosentan, demonstrating the safety of the drug for Japanese patients; however, 4 out of 28 patients had adverse events associated with liver function disorders, which are one of the characteristic adverse effects of bosentan. These results indicate that liver function needs to be monitored regularly in patients treated with bosentan. <h3>Disclosure of Interest</h3> None declared
Treatment with TKIs Overcomes Imatinib Resistance through the PLCgamma-1 Signaling Pathway In Imatinib Resistant Human CML Cell Lines
Authors: Alessandra Romano, Paolo Vigneri, Chiara Romano, Calogero Vetro, Stefania Stella, Michele Massimino, Fabio Stagno, Francesco Di Raimondo, Lance Liotta, Virginia Espina
Journal: Blood (2010)
An Adaptive-Design Dose-Ranging Study of PD 0348292, a New Oral Factor Xa Inhibitor, for Thromboprophylaxis after Total Knee Replacement Surgery.
Authors: Alexander T Cohen, Donald Armstrong, Tadeusz Gazdzik, Camilla Ryge, Raphael Pak, Jaap Mandema, Rebecca Boyd, Scott McBride, Lorenzo A. DiCarlo
Journal: Blood (2008)
Systematic Review of 18F-Fluorodeoxyglucose Positron Emission Tomography for Post-Treatment Evaluation of Malignant Lymphoma.
Authors: Josée M. Zijlstra, Otto S. Hoekstra, Gerda Lindauer-van der Werf, Lotty Hooft, Ingrid I. Riphagen, Peter C. Huijgens
Journal: Blood (2005)
Bortezomib Given in Sequence with Anthracycline and Thalidomide-Containing Regimens Does Not Adversely Affect Stem Cell Mobilization and Engraftment in Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation.
Authors: Geoffrey L. Uy, Nicholas M. Fisher, Steven M. Devine, Hanna J. Khoury, Douglas R. Adkins, Michael H. Tomasson, Timothy A. Graubert, John F. DiPersio, Ravi Vij
Journal: Blood (2004)